<DOC>
	<DOCNO>NCT00828594</DOCNO>
	<brief_summary>Phase 1 Evaluate safety tolerability RAD001 combination sorafenib patient advance hepatocellular cancer ( HCC ) determine maximum tolerate dose ( MTD ) Phase 2 To estimate treatment effect measure anti-tumor activity term Time Progression ( TTP ) combination RAD001 plus sorafenib , MTD , compare sorafenib alone</brief_summary>
	<brief_title>Global Study Looking Combination RAD001 Sorafenib Treat Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advanced liver cancer No previous systemic therapy liver cancer Measurable disease CT MRI ECOG 1 less ChildPugh A Active bleeding last 30 day Known history HIV seropositivity Any severe and/or uncontrolled medical condition include Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>dose-finding study</keyword>
	<keyword>randomize trial</keyword>
	<keyword>medical treatment</keyword>
	<keyword>RAD001</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Advanced hepatocellular cancer ( HCC )</keyword>
</DOC>